Screening for Down syndrome

References

• Wilson JMG, Jungner G. Principles and practice of screening for disease. Public Health Paper Number 34. Geneva: WHO, 1968.
   Google Scholar
• Merkatz IR, Nitowsky HM, Macri JN, et al. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984; 148:886–94.
   PubMed Web of Science ®Google Scholar
• Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984;1(8383):926–9.
   Google Scholar
• Cuckle HS, Wald NJ, Thomson SG. Estimating a women's risk of having a pregnancy associated with Down's syndrome using her age and serum alphafetoprotein level. Br J Obstet Gynaecol 1987;94:387–402.
   PubMedGoogle Scholar
• Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987;7: 623–30.
   PubMed Web of Science ®Google Scholar
• Canick JA, Knight GJ, Palomaki GE, et al. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988;95: 330–3.
   PubMedGoogle Scholar
• Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297:883–7.
   PubMed Web of Science ®Google Scholar
• Macri JN, Kasturi RV, Krantz DA, et al. Maternal serum Down syndrome screening: free beta protein is a more effective marker than human chorionic gonadotropin. Am J Obstet Gynecol 1990;163:1248–53.
   PubMed Web of Science ®Google Scholar
• Spencer K. Evaluation of an assay of the free beta-subunit of choriogonadotropin and its potential value in screening for Down's syndrome. Clin Chem 1991:37:809–14.
   PubMed Web of Science ®Google Scholar
• Spencer K, Wood PJ, Anthony FW. Elevated levels of maternal serum inhibin immunoreactivity in second trimester pregnancies affected by Down's syndrome. Ann Clin Biochem 1993;30:219–20.
   PubMed Web of Science ®Google Scholar
• Aitken DA, Wallace EM, Crossley JA, et al. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. N Engl J Med 1996;334:1231–6.
   PubMed Web of Science ®Google Scholar
• Wallace EM, Crossley JA, Ritoe SC, et al. Evolution of an inhibin A ELISA method: implications for Down's syndrome screening. Ann Clin Biochem 1998;35:656–64.
   Google Scholar
• Spencer K. Aneuploidy screening in the first trimester. Am J Med Genet Part C Semin Med Genet 2007;145C18–32.
   Google Scholar
• Cuckle H, Aitken D, Goodburn S, et al. Age-standardisation when target setting and auditing performance of Down syndrome screening programmes. Prenat Diagn 2004;24:851–6.
   PubMed Web of Science ®Google Scholar
• Lau TK, Evans MI. Second-trimester sonographic soft markers: what can we learn from experience of first trimester nuchal translucency screening? Ultrasound Obstet Gynecol 2008;32:123–5.
   PubMedGoogle Scholar
• Agathokleous M, Chaveeva P, Poon LCY, et al. Meta- analysis of second trimester markers for trisomy 21. Ultrasound Obstet Gynecol 2013;41:247–61.
   PubMed Web of Science ®Google Scholar
• Kagan KO, Wright D, Etchegaray A, et al. Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21. Ultrasound Obstet Gynecol 2009;33:657–64.
   PubMed Web of Science ®Google Scholar
• Spencer K, Souter V, Tul N, et al. A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free b-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231–7.
   PubMed Web of Science ®Google Scholar
• Wright D, Kagan KO, Molina FS, et al. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008;31:376–83.
   PubMed Web of Science ®Google Scholar
• Kagan KO, Wright D, Valencia C, et al. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free β-hCG and pregnancy-associated plasma protein-A. Hum Reprod 2008;23:1968–75.
   PubMed Web of Science ®Google Scholar
• Kagan KO, Wright D, Spencer K, et al. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008;31:493–502.
   PubMed Web of Science ®Google Scholar
• Morgan S, Delbarre A, Ward P. Impact of introducing a national policy for prenatal Down syndrome screening on the diagnostic invasive procedure rate in England. Ultrasound Obstet Gynecol 2013;41:526–9.
   PubMed Web of Science ®Google Scholar
• Madsen HN, Ball S, Wright D, et al. A re-assessment of biochemical marker distributions in T21 affected and unaffected twin pregnancies in the first trimester. Ultrasound Obstet Gynecol 2011;37:38–47.
   PubMed Web of Science ®Google Scholar
• Spencer K. Non-invasive screening tests. In Blickstein I, Keith L (eds.) Multiple pregnancy: epidemiology, gestation and perinatal outcome. Oxford: Taylor & Francis. 2005. pp. 368–4.
   Google Scholar
• Spencer K, Staboulidou I, Nicolaides KH. First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers. Prenat Diagn 2010;30:235–40.
   PubMed Web of Science ®Google Scholar
• Sankaran S, Rozette C, Dean J, et al. Screening in the presence of a vanished twin: nuchal translucency or combined screening test? Prenat Diagn 2011;31;600–01.
   Google Scholar
• Wald NJ, Rodeck C, Hackshaw AW, et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003;7:1–77.
   Google Scholar
• Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001–11.
   PubMed Web of Science ®Google Scholar
• Spencer K, Crossley JA, Aitken DA, et al. Temporal changes in maternal serum biochemical markers of Trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 2004;39:567–76.
   Google Scholar
• Spencer K, Crossley JA, Aitken DA, et al. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimester of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome. Ann Clin Biochem 2003;40:219–31.
   PubMed Web of Science ®Google Scholar
• Wright D, Spencer K, Kagan K, et al. First-trimester combined screening for trisomy 21 at 8–13 weeks. Ultrasound Obstet Gynecol 2010;30:404–11.
   Google Scholar
• Spencer K, Cowans NJ. Correction of first trimester biochemical aneuploidy screening markers for smoking status: influence of gestational age, maternal ethnicity and cigarette dosage. Prenat Diagn 2013;33:116–23.
   Google Scholar
• Cowans NJ, Spencer K. Effect of gestational age on first trimester maternal serum prenatal screening correction factors for ethnicity and IVF conception. Prenat Diagn 2013;33:56–60.
   Google Scholar
• Wright D, Bradbury I, Benn P, et al. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 2004;24:762–6.
   PubMed Web of Science ®Google Scholar
• Nicolaides KH, Spencer K, Avgidou K, et al. Multicentre study of first trimester screening for trisomy 21 in 75,821 pregnancies: results and estimation of the potential impact of individual risk orientated two stage first trimester screening. Ultrasound Obstet Gynecol 2005;25:221–6.
   PubMed Web of Science ®Google Scholar
• Chitty LS, Hill M, White H, et al. Noninvasive prenatal testing for aneuploidy – ready for prime time. Am J Obstet Gynecol 2012;206:269–75.
   PubMed Web of Science ®Google Scholar
• Nicolaides KH. Turning the pyramid of prenatal care. Fetal Diagn Ther 2011;29:183–96.
   PubMed Web of Science ®Google Scholar
• Pandya P, Wright D, Syngelaki A, et al. Maternal serum placental growth factor in prospective screening for aneuploidies at 8–13 weeks’ gestation. Fetal Diagn Ther 2012; 31:87–93.
   PubMed Web of Science ®Google Scholar
• Akolekar R, Syngelaki A, Poon L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013;33:8–15.
   PubMed Web of Science ®Google Scholar
• Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012;31:141–6.
   PubMed Web of Science ®Google Scholar